Mark A West
Overview
Explore the profile of Mark A West including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ryu S, Yamaguchi E, Modaresi S, Agudelo J, Costales C, West M, et al.
Chemosphere
. 2024 Nov;
367:143571.
PMID: 39504843
No abstract available.
2.
Ryu S, Yamaguchi E, Modaresi S, Agudelo J, Costales C, West M, et al.
Chemosphere
. 2024 May;
361:142390.
PMID: 38801906
Per- and polyfluoroalkyl substances (PFAS) encompass a diverse group of synthetic fluorinated chemicals known to elicit adverse health effects in animals and humans. However, only a few studies investigated the...
3.
Bi Y, Jordan S, King-Ahmad A, West M, Varma M
Clin Pharmacol Ther
. 2024 Feb;
115(6):1336-1345.
PMID: 38404228
Daprodustat is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved recently for the treatment of anemia caused by chronic kidney disease (CKD) in adults receiving dialysis. We evaluated the...
4.
Bi Y, Jordan S, King-Ahmad A, West M, Yamaguchi E, Ryu S, et al.
Drug Metab Dispos
. 2024 Feb;
52(5).
PMID: 38388380
Organic anion transporting polypeptide (OATP1B) plays a key role in the hepatic clearance of a majority of high molecular weight (MW) acids and zwitterions. Here, we evaluated the role of...
5.
Huh Y, Plotka A, Wei H, Kaplan J, Raha N, Towner J, et al.
Pharm Res
. 2023 Aug;
40(11):2639-2651.
PMID: 37561322
Purpose: Ritlecitinib, an inhibitor of Janus kinase 3 and tyrosine kinase expressed in hepatocellular carcinoma family kinases, is in development for inflammatory diseases. This study assessed the impact of ritlecitinib...
6.
Lazzaro S, West M, Eatemadpour S, Feng B, Varma M, Rodrigues A, et al.
J Pharm Sci
. 2023 Jan;
112(6):1715-1723.
PMID: 36682487
P-glycoprotein (P-gp) may limit oral drug absorption of substrate drugs due to intestinal efflux. Therefore, regulatory agencies require investigation of new chemical entities as possible inhibitors of P-gp in vitro....
7.
Kimoto E, Costales C, West M, Bi Y, Vourvahis M, Rodrigues A, et al.
Clin Pharmacol Ther
. 2021 Oct;
111(2):404-415.
PMID: 34605015
Quantitative prediction of drug-drug interactions (DDIs) involving organic anion transporting polypeptide (OATP)1B1/1B3 inhibition is limited by uncertainty in the translatability of experimentally determined in vitro inhibition potency (half-maximal inhibitory concentration...
8.
Costales C, Lin J, Kimoto E, Yamazaki S, Gosset J, Rodrigues A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Jun;
10(9):1018-1031.
PMID: 34164937
Quantitative assessment of drug-drug interactions (DDIs) involving breast cancer resistance protein (BCRP) inhibition is challenged by overlapping substrate/inhibitor specificity. This study used physiologically-based pharmacokinetic (PBPK) modeling to delineate the effects...
9.
Patel N, Feng B, Hou X, West M, Trapa P, Sciabola S, et al.
ACS Chem Neurosci
. 2021 Mar;
12(6):1007-1017.
PMID: 33651587
One of the objectives within the medicinal chemistry discipline is to design tissue targeting molecules. The objective of tissue specificity can be either to gain drug access to the compartment...
10.
Eng H, Bi Y, West M, Ryu S, Yamaguchi E, Kosa R, et al.
J Pharmacol Exp Ther
. 2021 Jan;
377(1):169-180.
PMID: 33509903
It is generally presumed that uptake transport mechanisms are of limited significance in hepatic clearance for lipophilic or high passive-permeability drugs. In this study, we evaluated the mechanistic role of...